Ei.Ventures And Mycotopia To Merge Into New Psychedelic Mushroom Company
Two companies in the psychedelics space have signed a definitive agreement to merge.
Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End
Psychedelics biotech company Clearmind Medicine Inc.
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022.
Sundial Growers Shares Soar 21% After Company Posts Q1 Earnings
Earnings are out for Canadian cannabis LP Sundial Growers Inc. (NASDAQ: SNDL), which published its financials for the first quarter of the year, ended March 31, 2022.
Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development
Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ending March 31, 2022.
Field Trip Launches At-Home Ketamine Treatment In Partnership With Nue Life
Field Trip Health (NASDAQ: FTRP), a company offering mental health treatment using ketamine therapy, has inked a unique deal with Nue Life Health to expand its service offerings to at-home treatment.
EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline into a separate public company that will also be listed on the NASDAQ, and will be called Acanna Therapeutics Inc.
EXCLUSIVE: Kevin Harrington Becomes The Latest ‘Shark Tank’ Judge To Enter The Psychedelics Space
The psychedelics industry is quickly becoming the latest playground for celebrity investors and influencers in the financial sphere.
Kevin Harrington, one of the original “sharks” in ABC's “Shark Tank” is joining a psychedelics company as an investor and strategic advisor.
Two New Studies Look At Compass Pathways’ Psilocybin Drug For Anorexia And Depression
Compass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.